Zinc Supplementation and Cardiovascular Risk in HIV

Inclusion Criteria: * HIV-1 infection * Age ≥18 years * Zinc level ≤0.75 mg/L * Receiving a stable antiretroviral regimen with no plans to change during study * Documentation of an HIV-1 RNA level of ≤400 copies/mL * No diarrhea or nausea/vomiting for the last month Exclusion Criteria: * Pregnancy/lactation * Presence of inflammatory condition * Regular use of agents that may affect inflammation in the last 3 months. The regular use of NSAIDS, aspirin, or statins will be allowed as long as dose has been stable for the last 3 months and is not expected to change during the study. * Presence of active neoplastic diseases requiring chemotherapy and/or use of immunosuppressive drugs * Known cardiovascular disease * Uncontrolled diabetes * Allergy or intolerance to zinc sulfate. * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \> 2.5 x Upper limit of normal (ULN) * Hemoglobin \< 9.0 g/dL * glomerular filtration rate (GFR) \< 50 mL/min